Grounded valuation assumes a sustainable EV/EBITDA multiple of ~12x on 2025 EBITDA (implied by $8.1B FCF, robust margins, and industry comps), incorporating biosimilar and pricing headwinds but also pipeline upside. Share count based on latest reported (545M). Growth sustainability is strong but no…
Amgen (AMGN) Q4 2025: 13 Products Drive Double-Digit Growth as Rare Disease Tops $5B
Amgen’s breadth of growth drivers—spanning rare disease, biosimilars, and innovative oncology—powered robust top- and bottom-line expansion in 2025, despite looming competitive threats. Management’s 2026 outlook signals confidence in pipeline launches and margin discipline, while the obesity franchise emerges as a future-defining lever. Investor focus now turns to pipeline execution and the durability of growth in the face of biosimilar headwinds and pricing pressure.
Summary
- Pipeline Depth Expands: Late-stage programs in obesity, cardiometabolic, and rare disease set up multi-year growth.
- Biosimilar and Competitive Pressures: Margin and revenue headwinds intensify as denosumab biosimilars and price erosion accelerate.
- Obesity Franchise Emerges: Meritide’s infrequent dosing profile positions Amgen to compete in the next era of metabolic disease.
Business Overview
Amgen is a global biotechnology company specializing in innovative and biosimilar medicines. Revenue is generated through a portfolio of branded biologics and biosimilars, with major segments including general medicine (cardiometabolic and bone health), rare disease, inflammation, oncology, and biosimilars. The company’s business model leverages blockbuster therapies (products with over $1 billion in annual sales), late-stage pipeline assets, and global commercial reach to drive growth.
Performance Analysis
Amgen’s 2025 performance was defined by broad-based growth, operational discipline, and strategic reinvestment. The company reported double-digit increases in both revenue and earnings per share, underpinned by 14 blockbuster products and 13 medicines posting double-digit sales gains. Rare disease sales surpassed $5 billion, while biosimilars contributed $3 billion, reflecting a strong expansion from both legacy and emerging franchises.
Operating margin remained robust at 46% despite a 22% increase in R&D spending to $7.2 billion, a signal of aggressive pipeline investment. The company generated $8.1 billion in free cash flow, retired $6 billion in debt, and increased its dividend, underscoring a balanced approach to growth and shareholder returns. However, management flagged accelerating competition from biosimilars (notably for denosumab/Prolia) and ongoing price pressure as offsetting factors for 2026, with first-quarter revenue growth expected to slow due to seasonality and inventory dynamics.
- Rare Disease Portfolio Momentum: Grew 14% YoY, now nearly $5.2 billion, fueled by new indications and geographic expansion.
- Oncology and Biosimilars: Innovative oncology up 11% YoY to $8.7 billion; biosimilars up 37% YoY, reflecting durable cash flow and market access strength.
- Margin and Cash Flow Discipline: Maintained high operating margin and free cash flow while scaling R&D and capital expenditures for pipeline launches.
Growth was broad-based but faces near-term headwinds from biosimilar launches and pricing, especially in bone health and established inflammation therapies. The company’s ability to offset these with new launches and pipeline execution remains the central investor question.
Executive Commentary
"The strength of that broad portfolio enabled us to post double-digit growth in revenues and earnings per share for 2025... these products represent growth drivers not just for 2026, but for the rest of the decade."
Bob Bradway, Chairman and Chief Executive Officer
"We continue to invest in advancing our pipeline with non-GAAP R&D spending increased 22% year-over-year... reflecting increased spending on an unprecedented number of opportunities in our late-stage pipeline."
Peter Griffith, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Obesity Franchise and Cardiometabolic Expansion
Meritide, Amgen’s late-stage obesity therapy, is positioned as a paradigm-shifting asset with potential for monthly, every-other-month, or quarterly dosing—differentiating it from weekly GLP-1s. The pipeline also includes AMG513 and other undisclosed assets, signaling intent to compete broadly in metabolic disease. Cardiometabolic leadership is reinforced by Repatha and the advancing Opaziran program, aiming to build a multi-asset franchise in chronic disease management.
2. Rare Disease and Autoimmune Portfolio Scale
Rare disease medicines generated over $5 billion, with Aplizna’s expansion into new indications (IgG4-related disease, myasthenia gravis) and geographies. The company is pursuing additional autoimmune indications (autoimmune hepatitis, CIDP), leveraging its B-cell depletion platform to drive further growth and address high unmet needs.
3. Oncology Innovation and Bispecifics Platform
Innovative oncology sales rose 11%, led by rapid adoption of Imdeltra and sustained momentum for Blincyto. The bispecific T-cell engager platform is extending into new indications (e.g., prostate cancer, Ewing sarcoma), with Imdeltra now standard of care in small cell lung cancer. Portfolio rationalization (e.g., discontinuation of bimerituzumab) reflects a focus on high-probability, high-impact assets.
4. Biosimilars as Growth and Access Engine
Biosimilars contributed $3 billion in 2025, with PavBlue (ILEA biosimilar) gaining traction among retina specialists. Amgen’s experience and supply reliability position it to defend share as competition intensifies, though pricing and volume dynamics will require continued commercial agility.
5. Capital Allocation and Manufacturing Readiness
Amgen invested $2.2 billion in capital expenditures to scale manufacturing for pipeline launches, notably Meritide. Balance sheet strength, debt reduction, and a growing dividend support continued investment in innovation while maintaining shareholder returns.
Key Considerations
Strategic context for the quarter centers on managing near-term competitive threats while scaling for future-defining launches. The breadth of growth drivers provides resilience, but execution risk rises as legacy products face biosimilar erosion and pricing headwinds.
Key Considerations:
- Obesity Pipeline Execution: Meritide’s differentiated dosing profile could unlock new patient segments, but clinical data and regulatory timelines will be pivotal.
- Biosimilar Competition Intensifies: Prolia/denosumab faces immediate biosimilar launches, pressuring revenue and margin in bone health.
- Rare Disease Uptake: Aplizna’s expansion into new indications and geographies is driving growth, but market size estimates remain fluid as diagnosis rates rise.
- R&D Investment Ramp: Elevated R&D spend signals pipeline confidence but raises the bar for late-stage asset delivery and commercial execution.
- Capital Allocation Balance: Continued investment in manufacturing and pipeline launches must be balanced against dividend growth and share repurchases.
Risks
Amgen faces material risks from biosimilar launches and price erosion in core franchises (notably Prolia, Otezla, and other established brands). Pipeline execution risk is elevated given the scale of late-stage programs, with regulatory and clinical trial outcomes for Meritide and other assets critical to long-term growth. Macroeconomic factors, payer dynamics, and global reimbursement trends also pose ongoing volatility, especially as the company expands in rare disease and metabolic indications.
Forward Outlook
For Q1 2026, Amgen guided to:
- Lower mid-single-digit YoY revenue growth, reflecting seasonality, insurance cycle headwinds, and $250 million inventory build impact.
- Lowest non-GAAP operating margin of the year, in line with Q4 2025.
For full-year 2026, management guided:
- Total revenues of $37.0 billion to $38.4 billion
- Non-GAAP EPS of $21.60 to $23.00
- Operating margin of 45 to 46 percent
- R&D expense to grow low single digits (excluding 2025’s $300 million BD transactions)
- Share repurchases not to exceed $3 billion
Management emphasized that growth in six key drivers (Repatha, Avenity, Tespire, rare disease, innovative oncology, biosimilars) will offset biosimilar and pricing headwinds, and positioned 2026 as a “springboard” for future growth, with Meritide and other pipeline launches on the horizon.
- Seasonal headwinds expected in Q1 tied to U.S. insurance cycles and product-specific trends.
- Capital expenditure guidance of $2.6 billion, focused on manufacturing scale for pipeline launches.
Takeaways
Amgen’s diversified growth engine delivered in 2025, but the next chapter hinges on pipeline execution and competitive resilience.
- Obesity and Cardiometabolic Franchise: Meritide’s infrequent dosing and pipeline breadth could redefine Amgen’s growth profile if clinical results and market adoption deliver as anticipated.
- Biosimilar and Pricing Headwinds: Revenue and margin pressure from denosumab and other biosimilars will test Amgen’s ability to backfill with new launches and expand in rare disease.
- Investor Watchpoint: Track Meritide’s clinical milestones, rare disease uptake, and commercial traction for biosimilars as leading indicators of Amgen’s ability to sustain multi-year growth.
Conclusion
Amgen enters 2026 with strong momentum, a broad base of growth drivers, and a pipeline poised to shape the next era of metabolic and rare disease treatment. Execution on late-stage assets and resilience against biosimilar erosion will be decisive for sustaining valuation and long-term leadership.
Industry Read-Through
Amgen’s results reinforce several industry-wide themes: Blockbuster diversification and pipeline breadth are critical for navigating patent cliffs and biosimilar competition. The obesity market’s shift to infrequent dosing and combination therapies will drive the next wave of innovation and commercial battles, with implications for both biotech and large-cap pharma. Biosimilar adoption is accelerating across categories, pressuring legacy brands and requiring commercial agility. R&D investment discipline and capital allocation balance remain central as the sector faces rising cost of capital and payer scrutiny. Other biopharma players should note the increasing importance of rare disease expansion, pipeline differentiation, and manufacturing readiness as competitive levers in the coming cycle.